Skip to main content

Table 1 Patients’ characteristics at baseline, by HBeAg status

From: Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy

Characteristics All patients (n = 47) HBeAg positive (n = 25) HBeAg negative (n = 22)
Age (years) 55 (27–80) 55 (27–80) 57 (35–80)
Males 31 (70.0) 15 (60.0) 16 (72.7)
Albumin (g/dL) 4.1 (2.4–4.6) 4.0 (2.4–4.6) 4.1 (3.5–4.6)
ALT (IU/L) 58 (14–538) 72 (29–522) 45 (14–538)
Total bilirubin (mg/dL) 0.8 (0.3–3.7) 0.8 (0.4–2.4) 0.9 (0.3–3.7)
Cirrhosis 14 (29.8) 6 (24.0) 8 (36.4)
HBV-DNA (log IU/mL) 5.7 (1.3–8.2) 6.8 (1.7–8.2) 4.4 (1.3–7.7)
HBsAg (log IU/mL) 3.3 (− 0.1 to 4.8) 3.5 (2.7–4.8) 3.3 (− 0.1 to 4.0)
HBcrAg (log U/mL) 5.7 (2.9–7.0) 7.0 (5.4–7.0) 4.1 (2.9–6.4)
  1. Data are expressed as median (range) or number (%)
  2. ALT alanine aminotransferase, HBcrAg hepatitis B core-related antigen, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus